[go: up one dir, main page]

GB201908573D0 - Compounds and methods of use - Google Patents

Compounds and methods of use

Info

Publication number
GB201908573D0
GB201908573D0 GBGB1908573.7A GB201908573A GB201908573D0 GB 201908573 D0 GB201908573 D0 GB 201908573D0 GB 201908573 A GB201908573 A GB 201908573A GB 201908573 D0 GB201908573 D0 GB 201908573D0
Authority
GB
United Kingdom
Prior art keywords
compounds
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1908573.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Edinburgh Molecular Imaging Ltd
Original Assignee
Edinburgh Molecular Imaging Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edinburgh Molecular Imaging Ltd filed Critical Edinburgh Molecular Imaging Ltd
Priority to GBGB1908573.7A priority Critical patent/GB201908573D0/en
Publication of GB201908573D0 publication Critical patent/GB201908573D0/en
Priority to SG11202113333SA priority patent/SG11202113333SA/en
Priority to MX2021015467A priority patent/MX2021015467A/en
Priority to GB2009064.3A priority patent/GB2589398B/en
Priority to PCT/GB2020/051442 priority patent/WO2020249980A1/en
Priority to BR112021025124A priority patent/BR112021025124A2/en
Priority to JP2021574189A priority patent/JP2022537946A/en
Priority to CA3142866A priority patent/CA3142866A1/en
Priority to US17/618,850 priority patent/US20220273830A1/en
Priority to EP20734286.6A priority patent/EP3983019A1/en
Priority to CN202080057163.7A priority patent/CN114222592A/en
Priority to KR1020227000907A priority patent/KR20220034777A/en
Priority to GB2115731.8A priority patent/GB2598676A/en
Priority to AU2020291197A priority patent/AU2020291197A1/en
Ceased legal-status Critical Current

Links

GBGB1908573.7A 2019-06-14 2019-06-14 Compounds and methods of use Ceased GB201908573D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1908573.7A GB201908573D0 (en) 2019-06-14 2019-06-14 Compounds and methods of use
AU2020291197A AU2020291197A1 (en) 2019-06-14 2020-06-15 Compounds and methods of use
JP2021574189A JP2022537946A (en) 2019-06-14 2020-06-15 Compounds and methods of using them
US17/618,850 US20220273830A1 (en) 2019-06-14 2020-06-15 Compounds and methods of use
GB2009064.3A GB2589398B (en) 2019-06-14 2020-06-15 Compounds and methods of use
PCT/GB2020/051442 WO2020249980A1 (en) 2019-06-14 2020-06-15 Compounds and methods of use
BR112021025124A BR112021025124A2 (en) 2019-06-14 2020-06-15 Compound, pharmaceutical composition, kit for preparing the pharmaceutical composition, methods of imaging and radiotherapy of the mammalian body, detection, diagnosis, prognosis, outcome prediction, surgery, staging, treatment, therapy, radiotherapy, treatment monitoring, disease progression and/or monitoring of therapy and obtaining site imaging and/or treatment of conditions associated with overexpression or localization of cmet in vivo, and, use
SG11202113333SA SG11202113333SA (en) 2019-06-14 2020-06-15 Compounds and methods of use
CA3142866A CA3142866A1 (en) 2019-06-14 2020-06-15 Compound comprising a cmet binding cyclic peptide for human or animal administration and uses thereof
MX2021015467A MX2021015467A (en) 2019-06-14 2020-06-15 Compounds and methods of use.
EP20734286.6A EP3983019A1 (en) 2019-06-14 2020-06-15 Compounds and methods of use
CN202080057163.7A CN114222592A (en) 2019-06-14 2020-06-15 Compounds and methods of use
KR1020227000907A KR20220034777A (en) 2019-06-14 2020-06-15 Compounds and Methods of Use
GB2115731.8A GB2598676A (en) 2019-06-14 2020-06-15 Compounds and methods of use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1908573.7A GB201908573D0 (en) 2019-06-14 2019-06-14 Compounds and methods of use

Publications (1)

Publication Number Publication Date
GB201908573D0 true GB201908573D0 (en) 2019-07-31

Family

ID=67432227

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1908573.7A Ceased GB201908573D0 (en) 2019-06-14 2019-06-14 Compounds and methods of use

Country Status (1)

Country Link
GB (1) GB201908573D0 (en)

Similar Documents

Publication Publication Date Title
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL276687A (en) Trialkyne linking agents and methods of use
IL292810A (en) Therapeutic compounds and methods of use
IL287751A (en) Kcnt1 inhibitors and methods of use
SG11202112158YA (en) Kcnt1 inhibitors and methods of use
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL279475B2 (en) Ectonucleotidase inhibitors and methods of use thereof
IL285117A (en) Methods of characterizing condensate-associated characteristics of compounds and uses thereof
IL287973A (en) Acss2 inhibitors and methods of use thereof
SG11202112978WA (en) Auto-injector and related methods of use
IL276135A (en) Compositions and methods of use
ZA202100780B (en) Bismuth-thiol compositions and methods of use
IL286697A (en) Neuregulin-4 compounds and methods of use
IL276053A (en) Therapeutic-gard and method of use thereof
GB201903827D0 (en) New compounds and methods
GB201903832D0 (en) New compounds and methods
GB2589398B (en) Compounds and methods of use
GB201913110D0 (en) New compounds and methods
ZA202105399B (en) Use of spiropidion
EP3976039A4 (en) Bisaminoquinolines and bisaminoacridines compounds and methods of their use
GB201908573D0 (en) Compounds and methods of use
HK40053173B (en) Compounds and methods of use
HK40072716A (en) Compounds and methods of use
GB202004360D0 (en) Compounds and methods of use
HK40053358A (en) Anellosomes and methods of use

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)